- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | GENFLEET-B (02595): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026 | 1 | HKEx | ||
| Fr | GENFLEET-B (02595): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Fr | GENFLEET-B (02595): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| Fr | GENFLEET-B (02595): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 09.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH SECOND BREAKTHROUGH THERAPY DESIGNATION, AS THE FIRST KRAS G12D INHIBITOR MONOTHERAPY INCLUDED ... | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.03. | GENFLEET-B (02595): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) CHANGE OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 20.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRECLINICAL RESEARCH DATA OF THREE LARGE- AND SMALL-MOLECULE TARGETED THERAPIES RELEVANT TO RAS PATHWAY TO ... | 1 | HKEx | ||
| 11.03. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 09.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION INTO THE STOCK LIST OF THE STOCK CONNECT PROGRAM (SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG ... | 1 | HKEx | ||
| 02.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A KRAS G12D INHIBITOR TREATING NON-SMALL ... | 1 | HKEx | ||
| 13.02. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX | 4 | HKEx | ||
| 09.02. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 09.02. | GENFLEET-B (02595): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 9, 2026; AND (2) ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND ... | - | HKEx | ||
| 23.01. | GENFLEET-B (02595): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, FEBRUARY 9, 2026 | 4 | HKEx | ||
| 23.01. | GENFLEET-B (02595): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 23.01. | GENFLEET-B (02595): (1) PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME (2) PROPOSED ADOPTION OF THE H SHARE INCENTIVE SCHEME (3) PROPOSED AUTHORISATION ... | 2 | HKEx | ||
| 20.01. | GENFLEET-B (02595): PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 11,010 | +2,42 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| KAILERA THERAPEUTICS | 26,010 | 0,00 % | Kailera Therapeutics-Aktie: Bekommen Eli Lilly und Novo Nordisk nun Angst? | Es ist einer der heißesten Börsengänge im Biotech-Sektor dieses Jahr. Kailera Therapeutics feiert heute sein Börsendepüt an der Nasdaq. Das Biotech-Unternehmen will mit seinen Wirkstoffen den Adipositas-Markt... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 22,460 | 0,00 % | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 342,50 | +6,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| QIAGEN | 35,350 | +1,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | +2,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | +4,61 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| BIONTECH | 87,55 | +0,11 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| CG ONCOLOGY | 73,44 | +10,67 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| SUMMIT THERAPEUTICS | 25,140 | +2,95 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| EVOTEC | 5,640 | +1,26 % | Evotec: Kursziel bestätigt - Neue Chancen für Anleger? | ||
| IMMUNOVANT | 29,300 | +7,13 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CABALETTA BIO | 3,440 | -2,27 % | Cellares' Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy | ||
| ERASCA | 18,995 | +4,20 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,340 | +3,06 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.